Category Archives: Other

Sichuan Drug Regulator Opens Call for TCM Standards Drafting Units – First Batch Covers New and Revised Herbal Material and Decoction Piece Monographs

Chengdu, China – 15 Sep 2026 – The Office of the Sichuan Provincial Drug Administration (Sichuan MPA) has issued a province‑wide notice soliciting drafting units for the first batch of new and revised traditional Chinese medicine (TCM) standards, formally launching the revision cycle for the Sichuan Provincial Standards for TCM Materials (2010 Edition) and the Sichuan Provincial Processing Norms for TCM Decoction Pieces (2015 Edition). The call is open to drug testing institutions, universities and research institutes, and TCM production and R&D enterprises, with applications due by 8 October 2026.

Policy Snapshot

ItemDetail
Issuing AuthorityOffice of the Sichuan Provincial Drug Administration
InitiativeFirst batch of newly added and revised provincial TCM standards
Standards Under RevisionSichuan Provincial Standards for TCM Materials (2010 Edition); Sichuan Provincial Processing Norms for TCM Decoction Pieces (2015 Edition)
ScopeVarieties listed in Attachment 1 (new additions) and Attachment 2 (revisions); number of varieties not disclosed in the notice body
Eligible ApplicantsIndependently incorporated drug testing institutions, universities, research institutes, and TCM production/R&D enterprises
Submission Deadline8 October 2026 (based on time of receipt)
Funding ModelPrimarily self‑funded by drafting units; special subsidies or rewards‑in‑lieu‑of‑subsidies may be sought for annual key varieties that pass review
ContactsZhao Weiquan, Sichuan MPA, +86‑28‑8678‑6031; Qing Yan, Sichuan Institute for Drug Control, +86‑28‑8175‑4502

Scope of Work

  • Newly Added Varieties: Drafting units will conduct full quality‑standard research — literature verification, source origin, description, identification, checks, extractables, and content determination — and deliver a draft standard with drafting notes. Applications for new materials (including new botanical origins or new medicinal parts) must include origin verification, resource legality, safety, and clinical/medicinal evidence.
  • Revised Varieties: Units will perform verification research targeting the specific deficiencies identified in the catalogue (e.g., missing or outdated identification methods, unreasonable ash and extractable limits, inapplicable content‑determination methods), and may propose revisions beyond the listed issues.
  • Pharmacopoeia Alignment: Revisions must in principle be harmonized with the Chinese Pharmacopoeia 2025 Edition. Where Sichuan‑specific resources, clinical practice, or historical processing traditions justify divergence, applicants must submit comparative study data and rationale for expert panel adjudication.
  • Decoction Pieces Gap‑Filling: For decoction pieces lacking a corresponding material standard, the notice requires either establishing the material standard first or applying through an integrated material–decoction piece package, which is explicitly encouraged.

Eligibility & Selection Process

  • Qualifications: Applicants must hold independent legal‑person status with laboratory conditions, instrumentation, and technical staff adequate for TCM standards research; prior experience drafting or verifying national or provincial drug standards is a priority factor.
  • Integrity Requirement: No major drug quality/safety incidents or research misconduct records in the past three years.
  • Application Flexibility: One unit may apply for multiple varieties; multiple units may jointly apply for a single variety with a designated lead; applications for specific processing specifications within a multi‑specification variety are permitted.
  • Review Pathway: The Sichuan Institute for Drug Control will organize formal review, expert evaluation, and on‑site defense, then recommend a candidate list for Sichuan MPA approval and public announcement.
  • Submission: Two stamped paper copies to the Sichuan Institute for Drug Control (No. 8 Xinwen Road, Hi‑Tech Zone West, Pidu District, Chengdu), plus scanned and editable Word versions to zbbmsc@scidc.org.cn with the subject line “TCM Standards Drafting Unit Application + Unit Name.”

Industry Impact & Outlook

  • Standards Modernization: Upgrading monographs dating to 2010 and 2015 to align with the Chinese Pharmacopoeia 2025 Edition will reset quality benchmarks for TCM materials and decoction pieces produced and circulated in Sichuan, one of China’s key TCM resource provinces.
  • Strategic Opportunity: Participation gives testing institutions, academia, and TCM manufacturers direct influence over standard‑setting — positioning early entrants ahead of the compliance requirements that follow final adoption.
  • Funding Watch: Research funding remains largely self‑raised; the bureau’s pledge to pursue special subsidies for prioritized varieties could tilt participation toward larger, better‑resourced institutions.
  • Unclaimed Varieties: For varieties attracting no qualified applicants, the Sichuan MPA will make separate arrangements, leaving open the possibility of direct commissioning.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the selection of drafting units, the timeline for standard revision and promulgation, and potential funding support. Actual outcomes may differ due to expert review results, application volume, and final regulatory decisions by the Sichuan Provincial Drug Administration.-China Health Reform Pulse

Policy Source: http://yjj.sc.gov.cn/scyjj/gztz/2026/9/15/1d68c0260a94442cb77c1a3fdab01504.shtml

Joint Procurement Office Opens Price Confirmation for Compound Amino Acid Injection Subtypes – “Deemed Selection” Route Added to China’s 12th National VBP Round

Shanghai, China – 11 Sep 2026 – The National Joint Procurement Office of Organized Drug Volume‑Based Procurement (JPO) has issued an announcement launching a price confirmation process for subtypes of compound amino acid injections that did not secure selection in the 12th round of nationally organized volume‑based procurement (VBP). Qualifying manufacturers that accept prices at or below a benchmark set at 1.8× the highest selected price of the comparable specification of compound amino acid 18AA‑Ⅶ injection may obtain “deemed selection” status – without agreed procurement volumes – through a time‑limited online window closing 23 September 2026.

Procurement Milestone

ItemDetail
Issuing BodyNational Joint Procurement Office (JPO)
Announcement Date11 Sep 2026
Policy TypePrice confirmation for compound amino acid injection subtypes under the 12th national drug VBP
12th VBP TimelineProposed selection results 31 Jul 2026; official publication 6 Aug 2026; agreed‑volume allocation to medical institutions completed 7 Sep 2026
Price Benchmark1.8× the highest selected price of the comparable specification of compound amino acid 18AA‑Ⅶ injection (incl. 18AA‑Ⅶ‑SF), adjusted for each subtype’s specification, usage volume and price‑comparison relationship
Registration Window14 Sep 2026, 09:00 – 17 Sep 2026, 12:00 (material amendments until 17:00, 17 Sep)
Price Confirmation Window21 Sep 2026, 09:00 – 23 Sep 2026, 12:00; submitted prices are final and irrevocable; non‑submission equals waiver
PlatformNational Healthcare Security Service Platform (fuwu.nhsa.gov.cn), using 12th‑round VBP enterprise accounts

Price Confirmation Rules – “Deemed Selection” Conditions

A compound amino acid subtype is granted deemed selection (with no agreed procurement volume) only if all of the following are met simultaneously:

  • Benchmark Test: Accepted price does not exceed the applicable price‑comparison benchmark (anchored to 1.8× the highest selected price of 18AA‑Ⅶ).
  • Own‑Price Test: Accepted price does not exceed the manufacturer’s lowest national listed price for the same brand – excluding invalid listings such as “inactive zone” prices.
  • All‑Specifications Test: Where a manufacturer produces multiple specifications of the same subtype (differing in content, fill volume or packaging), every specification must participate and satisfy both tests above.
  • SF Equivalence: Specifications labeled “SF” and those without the SF designation are treated as the same subtype for price confirmation.
  • All‑or‑Nothing Discipline: If any single specification of a subtype fails the rules, or if a company selectively participates with only part of its specifications, the entire subtype is deemed waived.

Scope, Exclusions & Eligibility

  • Excluded Products: Compound amino acid 18AA‑Ⅶ injection itself (both selected and non‑selected in the 12th VBP); pediatric‑only subtypes (generic names marked “pediatric/children” or pediatric‑restricted labeling); products that are not reference‑listed preparations; and products that have not passed (or are not deemed to have passed) the generic quality and consistency evaluation (GQCE).
  • Eligibility: Enterprises must meet the declaration qualifications of the 12th VBP procurement document (GY‑YD2026‑1); products must hold a valid domestic registration approval obtained by 11 September 2026 (inclusive).
  • Submission Requirements: Registration materials (waived for subtypes already cleared in the 12th VBP registration phase), a price confirmation commitment letter, and each subtype/specification with its lowest national listed price backed by provincial platform screenshots. Where company‑submitted listing data conflicts with JPO verification, the JPO’s verified data prevails.

Compliance, Penalties & Market Consequences

  • Red/Yellow Label Relief: Products granted deemed selection are exempt from red/yellow price‑risk labeling; existing red or yellow marks will be revoked by provincial procurement platforms as listed prices are adjusted to the confirmed level.
  • Risk Labeling for the Rest: After price confirmation concludes, all non‑selected compound amino acid injection products – including 12th VBP non‑winners, non‑participants, and products ineligible for VBP or confirmation (GQCE‑excluded), but excluding pediatric subtypes – will be flagged red or yellow by JPO member units under listed‑price governance rules, warning hospitals of procurement risk.
  • Credit‑Based Revocation: Deemed selection is terminated if a company is rated “seriously dishonest” or “particularly seriously dishonest” under the drug price and procurement credit evaluation system for kickbacks, tax violations, monopoly distribution control or similar misconduct.
  • False‑Information Sanctions: Submitting falsified listing‑price information results in disqualification and potential placement on the “violation list.”
  • Supply Obligations: Deemed‑selected products must mirror selected‑drug requirements, including full traceability‑code upload, timely supply and guaranteed delivery.
  • No Late Additions: Subtypes that fail to obtain deemed selection receive no supplementation during the 12th VBP execution period; however, newly approved specifications accepting the rules may apply to the JPO for deemed‑selection status.

Market Impact & Outlook

  • Extended Price Discipline: The mechanism drags non‑selected compound amino acid subtypes toward the 1.8× benchmark, tightening the effective price ceiling across the entire amino acid injection category beyond the formally selected 18AA‑Ⅶ products.
  • Portfolio‑Level Bargaining: The all‑specifications, all‑or‑nothing rule forces manufacturers to align pricing across entire subtype portfolios, discouraging cherry‑picking and compressing arbitrage between specifications.
  • Label Arbitrage Ends: The red/yellow flagging of holdout products – combined with label removal for compliant ones – creates a direct commercial incentive for hospitals to avoid non‑confirmed products, effectively marginalizing price‑resistant brands.
  • Compressed Timeline: With registration closing 17 September and irreversible price submissions due 23 September, companies face a decision window of roughly two weeks to model pricing against both the benchmark and their own national lowest listed prices.
  • Awarded Prices: Subtype‑level benchmark values and the highest selected price of 18AA‑Ⅶ were not disclosed in the announcement.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the price confirmation process, deemed‑selection outcomes, red/yellow labeling enforcement and supply compliance for compound amino acid injection subtypes under China’s 12th national volume‑based procurement. Actual results may differ due to risks including enterprise pricing decisions, JPO verification outcomes, credit‑rating actions, and subsequent policy adjustments by the National Healthcare Security Administration.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/gjsdcg/2026/09/11/24423.shtml

Yunnan Publicizes Essential Drug Attribute Changes for 37 Online Trading Products – Notification‑Commitment Filing Launched Immediately

Kunming, China – 07 Sep 2026 – The Yunnan Provincial Government Procurement and Transfer Center has published the changes in drug attributes for online trading, covering 37 product entries realigned with the National Essential Drug List (2026 Edition), and announced that notification‑commitment filing (告知承诺备案) for essential‑drug status takes effect immediately for all listed products attributed as “Essential Drug (including former provincial supplement).”

Procurement Milestone

ItemDetail
Issuing AuthorityYunnan Provincial Government Procurement and Transfer Center
Notice TypePublic disclosure of drug attribute changes (online trading platform)
Policy BasisNational Essential Drug List (2026 Edition)
Scope37 product entries across injectables, inhalation solutions, oral solids, TCM preparations and topical dosage forms
Disclosure Date7 Sep 2026
Key ConstantsApproval numbers unchanged; procurement ceiling prices unchanged for all entries
Filing RequirementNotification‑commitment filing with the Yunnan Provincial Medical Products Administration (MPA) — effective immediately
Objection Window5 business days from the disclosure date

Attribute Changes at a Glance

CategoryEntriesRepresentative ProductsChange
Essential‑drug status retained32Esomeprazole sodium for injection, ambroxol injection, milrinone injection, somatostatin for injection, nintedanib esylate soft capsules, cilostazol tablets, edaravone–dexborneol injection, ipratropium bromide inhalation solution (7 entries), azithromycin dry suspensionEssential drug → Essential drug (2026 List)
Upgraded to essential drug3Dalteparin sodium injection; nadroparin calcium injection (2 specs) — Yantai Dongcheng Northern PharmaceuticalNon‑essential → Essential drug
Reclassified to former provincial supplement2Dengzhanxixin granules — Yunnan Plant PharmaceuticalEssential drug → Former provincial supplement (原省补)
  • Manufacturer Footprint: The batch spans roughly 20 producers, including Langtian Pharmaceutical (Hubei) (9 entries), Simcere Pharmaceutical, Chengdu Beit, Shaanxi Hanwang, and France‑based Laboratoire Unither, whose ipratropium bromide solution is bid through Sinopharm Distribution Center — evidence of continued import participation in Yunnan’s platform.

Essential Drug Filing Obligation

  • Who Must Act: All enterprises whose products carry the “Essential Drug (including former provincial supplement)” attribute in the disclosure.
  • Procedure: Complete the notification‑commitment filing per the Yunnan Provincial MPA’s published requirements, bringing a printed copy of this announcement to the designated filing site.
  • Filing Site: Reception Hall, 1st Floor, Yunnan Institute for Food and Drug Control (new building, 616 Kefa Road, Kunming); filing hotline 0871‑63112057.
  • Compliance Warning: Enterprises that fail to complete the filing bear the consequences — a clear signal that unfiled products risk losing essential‑drug procurement privileges on the platform.

Objection & Public Supervision

  • Applicant Enterprises: Queries on the disclosed information must be raised within 5 business days to the Center’s Drug & Device Procurement Section (0871‑63606934).
  • General Public & Third Parties: Objections to the disclosure are accepted within 5 business days by the Comprehensive Supervision Section (0871‑65330065), keeping the process open to public scrutiny.

Market Impact & Outlook

  • 2026 List Alignment: This batch operationalizes the National Essential Drug List (2026 Edition) at the provincial trading level, with price ceilings and approval numbers held steady — suppliers gain attribute certainty without repricing risk.
  • Anticoagulant Upgrade: The promotion of dalteparin and nadroparin from non‑essential to essential status strengthens the procurement position of Yantai Dongcheng Northern Pharmaceutical in Yunnan’s public‑hospital channel.
  • TCM Reclassification: Moving dengzhanxixin granules to the “former provincial supplement” track preserves preferential treatment for legacy provincial items even after national‑list streamlining.
  • Filing as Gatekeeper: The immediate‑effect notification‑commitment regime makes filing a de facto compliance checkpoint — enterprises should treat it as a short‑fuse administrative deadline tied directly to continued listing.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding filing completion, objection outcomes, and procurement treatment of the disclosed products. Actual results may differ due to risks including filing verification, third‑party objections, and subsequent announcements by the Yunnan Provincial MPA and the Center.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27813&CatalogId=3